KTbio Group has always been committed to solving the problem of
clinical drug use for patients, constantly conquering the challenges
of the disease, using high-quality drugs to improve the quality of
life of patients, and working hard for the benefit of human health.
Exclusive license for the commercialization of GLP-1 products in China
Exclusive license to develop and commercialize programmed therapeutic cells in Greater China
Exclusive license for the distribution and promotion of insulin products
Collaboration for clinical development and commercialization of MCM1 in China
Exclusive partnership to commercialize liposomal products utilizing NanoX™ in Mainland China
Priority for potential licensing or development of two ophthalmic-related disease products
Exclusive right to develop and commercialize Remitch in China
Partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology
Collaboration for clinical development and commercialization of multiple biosimilars in China
Potential licensing priorities for four inner ear disease related research products
Investment to research and develop early stage cancer drugs